SR ONE CAPITAL MANAGEMENT, LP Long-Term Concentrated

CIK: 0001910264 · Show all filings

Period: Q1 2023 (← Previous) (Next →)

Filing Date: May 19, 2023

Total Value ($000): $268,461 (100.0% shares, 0.0% debt)

Holdings (6)

ACLX ARCELLX INC. 63.1%

Value ($000) $169,455 Shares 5,500,007 Est. Cost $16.72 Unrealized +81.4%

DSGN DESIGN THERAPEUTICS INC 14.0%

Value ($000) $37,658 Shares 6,526,476 Est. Cost $16.67 Unrealized -55.1%

MLYS MINERALYS THERAPEUTICS 10.5%

Value ($000) $28,103 Shares 1,794,600 Est. Cost $16.83 Unrealized 0.0%

SPRY ARS PHARMACEUTICALS 9.7%

Value ($000) $26,124 Shares 4,012,903 Est. Cost $6.79 Unrealized +13.2%

NKTX NKARTA INC. 1.8%

Value ($000) $4,733 Shares 1,333,333 Est. Cost $13.12 Unrealized -63.9%

— EFFECTOR THERAPEUTICS INC 0.9%

Value ($000) $2,388 Shares 6,822,114 Est. Cost $8.28 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
ACLX	ARCELLX INC.	5,500,007	$169,455	63.1%	$16.72	+81.4%	COMMON STOCK	03940C100
DSGN	DESIGN THERAPEUTICS INC	6,526,476	$37,658	14.0%	$16.67	-55.1%	COM	25056L103
MLYS	MINERALYS THERAPEUTICS	1,794,600	$28,103	10.5%	$16.83	0.0%	COM	603170101
SPRY	ARS PHARMACEUTICALS	4,012,903	$26,124	9.7%	$6.79	+13.2%	COM	82835W108
NKTX	NKARTA INC.	1,333,333	$4,733	1.8%	$13.12	-63.9%	COM	65487U108
—	EFFECTOR THERAPEUTICS INC	6,822,114	$2,388	0.9%	$8.28	—	COM	28202V108